1-13 of 13
Salomon M. Stemmer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract P1-08-14: Differences in Recurrence Score (RS) results between primary and second primary breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry

Free
Shlomit Strulov Shachar, Michelle Leviov, Rinat Yerushalmi, Karen Drumea, Margarita Tokar, Lior Soussan-Gutman, Avital Bareket-Samish, Amir Sonnenblick, Noa Efrat Ben-Baruch, Shani Paluch-Shimon, Gil Bar Sela, Salomon M Stemmer
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): P1-08-14.
https://doi.org/10.1158/1538-7445.SABCS21-P1-08-14
Published: 15 February 2022
View articletitled, Abstract P1-08-14: Differences in Recurrence Score (RS) results between primary and second primary breast cancer (BC): Exploratory analysis of the Clalit Health Services (CHS) registry
Journal Articles

Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2− breast cancer

Free
Joyce O'Shaughnessy, Salomon M Stemmer, Howard A Burris, Yoon-Sim Yap, Gabe Sonke, Lowell Hart, Mario Campone, Katarina Petrakova, Eric P Winer, Wolfgang Janni, Pierfranco Conte, David A Cameron, Fabrice André, Carlos Arteaga, Juan Pablo Zarate, Arunava Chakravartty, Tetiana Taran, Fabienne Le Gac, Paolo Serra, Gabriel N Hortobagyi
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): GS2-01.
https://doi.org/10.1158/1538-7445.SABCS21-GS2-01
Published: 15 February 2022
View articletitled, Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2− breast cancer
Journal Articles

Abstract CT178: Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination deficiency (HRD): Initial results of the phase 2 KEYLYNK-007 study

Free
Michele Maio, Ronnie Shapira-Frommer, Timothy A. Yap, Tudor Ciuleanu, Henry Gomez, Andrew Hill, Iwona Lugowska, Ozgur Ozyilkan, Karina Vera, Seock-Ah Im, Anna Kryzhanivska, Serhii Lysenko, Michael Schenker, Salomon M. Stemmer, Sanatan Saraf, Razvan Cristescu, PhD, Fan Jin, Alexander Gozman, Miguel Quintela-Fandino
Journal: Cancer Research
Cancer Res (2021) 81 (13_Supplement): CT178.
https://doi.org/10.1158/1538-7445.AM2021-CT178
Published: 01 July 2021
View articletitled, Abstract CT178: Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) and/or homologous recombination deficiency (HRD): Initial results of the phase 2 KEYLYNK-007 study
Journal Articles

Cancer-Associated Fibroblasts Promote Aggressive Gastric Cancer Phenotypes via Heat Shock Factor 1–Mediated Secretion of Extracellular Vesicles

Available to Purchase
Nil Grunberg, Meirav Pevsner-Fischer, Tal Goshen-Lago, Judith Diment, Yaniv Stein, Hagar Lavon, Shimrit Mayer, Oshrat Levi-Galibov, Gil Friedman, Yifat Ofir-Birin, Li-Jyun Syu, Cristina Migliore, Eyal Shimoni, Salomon M. Stemmer, Baruch Brenner, Andrzej A. Dlugosz, David Lyden, Neta Regev-Rudzki, Irit Ben-Aharon, Ruth Scherz-Shouval
Journal: Cancer Research
Cancer Res (2021) 81 (7): 1639–1653.
https://doi.org/10.1158/0008-5472.CAN-20-2756
Published: 01 April 2021
View articletitled, Cancer-Associated Fibroblasts Promote Aggressive Gastric Cancer Phenotypes via Heat Shock Factor 1–Mediated Secretion of Extracellular Vesicles
Open the PDF for Cancer-Associated Fibroblasts Promote Aggressive Gastric Cancer Phenotypes via Heat Shock Factor 1–Mediated Secretion of Extracellular Vesicles in another window
Includes: Supplementary data
Journal Articles

Abstract GS4-10: Development and validation of a tool integrating the 21-gene recurrence score and clinicopathlogic features to individualize prognosis for distant recurrence and prediction of absolute chemotherapy benefit in early breast cancer

Free
Joseph A Sparano, Michael R Crager, Gong Tang, Robert J Gray, Salomon M Stemmer, Steve Shak
Journal: Cancer Research
Cancer Res (2021) 81 (4_Supplement): GS4-10.
https://doi.org/10.1158/1538-7445.SABCS20-GS4-10
Published: 15 February 2021
View articletitled, Abstract GS4-10: Development and validation of a tool integrating the 21-gene recurrence score and clinicopathlogic features to individualize prognosis for distant recurrence and prediction of absolute chemotherapy benefit in early breast cancer
Journal Articles

Abstract P1-10-16: Ethnicity, recurrence score (RS) distribution, and clinical outcomes in ER+ HER2-negative breast cancer (BC) patients (pts) in Israel

Free
Gil Bar Sela, Yousef Samih, Rinat Yerushalmi, Michelle Leviov, Noa Efrat Ben-Baruch, Iryna Kuchuk, Margarita Tokar, Tamar Peretz, Amir L Sonnenblick, Lior Soussan-Gutman, Avital Bareket-Samish, Georgeta Fried, Shani Paluch-Shimon, Bella Kaufman, Ariel Hammerman, Nicky Liebermann, Salomon M Stemmer
Journal: Cancer Research
Cancer Res (2020) 80 (4_Supplement): P1-10-16.
https://doi.org/10.1158/1538-7445.SABCS19-P1-10-16
Published: 15 February 2020
View articletitled, Abstract P1-10-16: Ethnicity, recurrence score (RS) distribution, and clinical outcomes in ER+ HER2-negative breast cancer (BC) patients (pts) in Israel
Journal Articles

Abstract C45: NT219, a novel bispecific inhibitor of STAT3 and IRS1/2, combined with chemotherapy or MEK inhibitor in gemcitabine-resistant pancreatic tumors, induced tumor regression

Free
Hadas Reuveni, Lana Kupershmidt, Neta Moskovits, Evgeny Solomonov, Salomon M Stemmer, Izhak Haviv
Journal: Cancer Research
Cancer Res (2019) 79 (24_Supplement): C45.
https://doi.org/10.1158/1538-7445.PANCA19-C45
Published: 13 December 2019
View articletitled, Abstract C45: NT219, a novel bispecific inhibitor of STAT3 and IRS1/2, combined with chemotherapy or MEK inhibitor in gemcitabine-resistant pancreatic tumors, induced tumor regression
Journal Articles

Abstract 1030: Circulating tumor cells from patients' blood induce tumors in a personalized xenograft mouse model: A functional approach to assess the patients' premetastatic disease state

Free
Netta R. Shraga, Amihai Lieberman, Neta Moskovits, Alejandro Livoff, Evgeny Solomonov, Inbar Ben Shachar, Aron Popovtzer, Salomon M. Stemmer*, Izhak Haviv*
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 1030.
https://doi.org/10.1158/1538-7445.AM2018-1030
Published: 01 July 2018
View articletitled, Abstract 1030: Circulating tumor cells from patients' blood induce tumors in a personalized xenograft mouse model: A functional approach to assess the patients' premetastatic disease state
Journal Articles

Abstract CT045: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers

Free
Fabrice Andre, Salomon M. Stemmer, Mario Campone, Katarina Petrakova, Shani Paluch-Shimon, Yoon-Sim Yap, Norbert Marschner, Arlene Chan, Cristian Villanueva, Lowell L. Hart, Carlos L. Arteaga, Gabe S. Sonke, Eva-Maria Grischke, Emilio Alba, Arnd Nusch, Denise A. Yardley, Erik Jakobsen, Sibel Blau, Sara M. Tolaney, Faye Su, Wei He, Caroline Germa, Gabriel N. Hortobagyi
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT045.
https://doi.org/10.1158/1538-7445.AM2017-CT045
Published: 01 July 2017
View articletitled, Abstract CT045: Ribociclib + letrozole for first-line treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers
Journal Articles

Abstract 679: CF102 induces apoptosis of hepatocellular carcinoma

Free
Shira Cohen, Faina Barer, Salomon M. Stemmer, Pnina Fishman
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): 679.
https://doi.org/10.1158/1538-7445.AM2015-679
Published: 01 August 2015
View articletitled, Abstract 679: CF102 induces apoptosis of hepatocellular carcinoma
Journal Articles

Abstract 3840: Cetuximab-induced testicular toxicity

Free
Mattan Levi, Aaron Popovtzer, Moran Tzabari, Salomon M. Stemmer, Ruth Shalgi, Irit Ben-Aharon
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 3840.
https://doi.org/10.1158/1538-7445.AM2014-3840
Published: 01 October 2014
View articletitled, Abstract 3840: Cetuximab-induced testicular toxicity
Journal Articles

Abstract 4168: The role of miRNA-125a-Fyn interplay in prostate cancer tumorigenesis.

Free
Lihi Ninio Many, Irit Ben-Aharon, Sofia Zilber, Mattan Levy, Salomon M. Stemmer, Ruth Shalgi
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): 4168.
https://doi.org/10.1158/1538-7445.AM2013-4168
Published: 15 April 2013
View articletitled, Abstract 4168: The role of miRNA-125a-Fyn interplay in prostate cancer tumorigenesis.
Journal Articles

High-Dose 90Y Mx-Diethylenetriaminepentaacetic Acid (DTPA)-BrE-3 and Autologous Hematopoietic Stem Cell Support (AHSCS) for the Treatment of Advanced Breast Cancer: A Phase I Trial

Free
David M. Schrier, Salomon M. Stemmer, Timothy Johnson, Ravindra Kasliwal, James Lear, Steven Matthes, Sharon Taffs, Christopher Dufton, Stephan D. Glenn, Gregory Butchko, Robert L. Ceriani, Douglas Rovira, Paul Bunn, Elizabeth J. Shpall, Scott I. Bearman, Malcom Purdy, Pablo Cagnoni, Roy B. Jones
Journal: Cancer Research
Cancer Res (1995) 55 (23_Supplement): 5921s–5924s.
Published: 01 December 1995
View articletitled, High-Dose 90Y Mx-Diethylenetriaminepentaacetic Acid (DTPA)-BrE-3 and Autologous Hematopoietic Stem Cell Support (AHSCS) for the Treatment of Advanced Breast Cancer: A Phase I Trial
Open the PDF for High-Dose 90Y Mx-Diethylenetriaminepentaacetic Acid (DTPA)-BrE-3 and Autologous Hematopoietic Stem Cell Support (AHSCS) for the Treatment of Advanced Breast Cancer: A Phase I Trial in another window